Publications by authors named "Juliette Lodovichetti"
Article Synopsis
- Rituximab (RTX) is a key treatment for various autoimmune and chronic inflammatory diseases but increases the risk of severe infections and lowers vaccine effectiveness due to its impact on B cell responses.
- During the COVID-19 pandemic, RTX-treated patients faced heightened disease severity, which led to delays or avoidance of RTX treatments to protect against SARS-CoV-2 infections.
- A study of thirteen patients showed that while some had positive T cell responses post-vaccination, those recently treated with RTX had significantly lower antibody responses, suggesting a need for caution in timing vaccinations relative to RTX infusions to optimize immune protection.
